FIELD: medicine.
SUBSTANCE: group of inventions refers to a compound for prostate cancer diagnosis in a human or an animal, to a pharmaceutical composition, to application and diagnostic technique and methods for detecting prostate cancer. The compound contains at least one guide module which is able for interaction with a specific molecular prostate cancer marker specified in a group consisting of DD3 and telomerase reverse transcriptase (TERT), and at least one detected component specified in a group consisting of fluorescein or other related derivatives.
EFFECT: invention provides simplified prostate cancer diagnosis in vivo.
12 cl
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR CLASSIFYING PATIENTS WITH SOLID CANCER | 2017 |
|
RU2745730C2 |
| PHOSPHODIESTERASE 9A AS MARKER OF MALIGNANT TUMOR OF PROSTATE GLAND | 2010 |
|
RU2592668C2 |
| COMPOSITIONS AND METHODS FOR PROSTATE CANCER ANALYSIS | 2012 |
|
RU2641968C2 |
| DIAGNOSIS METHOD FOR USING A SOLUTION | 2003 |
|
RU2315312C2 |
| REPRESENTATIVE DIAGNOSIS | 2016 |
|
RU2743169C2 |
| NOVEL ACTIVITY-BASED PROBES FOR NEUTROPHIL ELASTASE AND USE THEREOF | 2019 |
|
RU2823716C2 |
| PHOSPHODIESTERASE 4D7 AS MARKER FOR AGGRESSIVE HORMONE-SENSITIVE PROSTATE CANCER | 2010 |
|
RU2575076C2 |
| CANCER BIOMARKERS | 2007 |
|
RU2460075C2 |
| METHODS OF DETECTING 5T4-POSITIVE CIRCULATING TUMOR CELLS AND METHODS OF DIAGNOSTICS OF 5T4-POSITIVE CANCER IN MAMMALS | 2013 |
|
RU2646498C2 |
| FLUORESCENT CONJUGATES AND USE THEREOF FOR TUMOR DIAGNOSTICS | 2016 |
|
RU2720976C2 |
